Stockwinners Market Radar for July 07, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:17 EDT JetBlue 'encouraged' by discussions with Spirit Airlines - JetBlue (JBLU) issued the following statement from Robin Hayes, chief executive officer, regarding the decision by the Spirit (SAVE) Board of Directors to adjourn its special meeting: "We are encouraged by our discussions with Spirit and are hopeful they now recognize that Spirit shareholders have indicated their clear, overwhelming preference for an agreement with JetBlue. We strongly recommend that Spirit shareholders continue to let the Spirit Board know they want to receive the superior value JetBlue has proposed, by voting AGAINST the Frontier (ULCC) transaction."

19:02 EDT Teck Resources reports Q2 steelmaking coal sales 6.3M tonnes - Teck Resources provided unaudited second quarter 2022 steelmaking coal sales volumes and realized prices. The company's realized second quarter steelmaking coal sales were 6.3M tonnes, within the previously announced guidance of 6.3M-6.7M tonnes. Record steelmaking coal FOB prices resulted in an increase in Teck's average realized steelmaking coal price in the second quarter to $453 per tonne. The company expects to record provisional pricing adjustments of negative $73M in the quarter due to the decline in coal prices at quarter end.

17:54 EDT U.S. Treasury outlines 'framework' for international cryptocurrency regulation - The U.S. Department of the Treasury adopted a fact sheet on working with foreign regulators to monitor the cryptocurrency market. The Treasury Department said in part earlier: "The Secretary of the Treasury, in consultation with the Secretary of State, the Secretary of Commerce, the Administrator of the U.S. Agency for International Development... delivered to President Biden a framework for interagency engagement with foreign counterparts and in international fora as directed in the President's Executive Order on Ensuring Responsible Development of Digital Assets...The Executive Order outlined an interagency approach to address the risks and harness the potential benefits of digital assets and their underlying technology, including through international engagement to adapt, update, and enhance adoption of global principles and standards for how digital assets are used and transacted. The Executive Order also directs the Administration to promote development of digital asset and central bank digital currencies, CBDC, technologies consistent with our values and legal requirements." Companies that may be impacted by this include Bitcoin (BTC), Ethereum ($ETH) Coinbase (COIN), Riot Blockchain ( (RIOT) ), Marathon Digital, (MARA) and Bitcoin Investment Trust (GBTC). Reference Link

17:51 EDT Sphere 3D reports June bitcoin production of 12.19 - Sphere 3D provided results of its Bitcoin mining operation as of June 30. From June 1 through June 30, Sphere 3D's mining operation produced 12.19 Bitcoin, or an average of 0.41 Bitcoin daily. The daily production level remained flat compared to May. The equivalent approximate valuation of the company's production, based on a Bitcoin price of $19,889 on June 30, 2022, totaled approximately $242,500 for the month. Since the company began its mining operations during the first quarter of 2022, it has produced 55.26 coins and held 49.23 Bitcoin on June 30. This represented a valuation of about $1M based on the Bitcoin price of $19,889 on June 30, 2022. The company continues to employ a HODL strategy and has not liquidated Bitcoin since commencing mining operations. The difference between the number of Bitcoin mined versus its holdings is the Bitcoin Sphere 3D used to pay operational expenses to partners. As of June 30, the company was operating approximately 1,000 S19j Pros miners delivering a production capacity of about 100 PH/s. Sphere 3D's mining fleet operated at 128 BTC/EH efficiency in June and averaged 97% uptime.

17:36 EDT PG&E, Tesla launch new pilot program to create virtual power plant - Pacific Gas and Electric Company (PCG) and Tesla (TSLA) have launched a new pilot program that creates a virtual power plant, to "help support electric grid reliability and save customers money." On June 22, Tesla invited approximately 25,000 PG&E customers with Powerwalls to join the VPP and help form the world's largest distributed battery. In the first two weeks of the new program, more than 3,000 customers have expressed interest in enrolling, with more than 1,500 customers officially in the program. Through this collaboration, Tesla is participating in PG&E's Emergency Load Reduction Program pilot by enrolling and combining residential Powerwall home battery systems into a virtual power plant to discharge power back to the grid in California during times of high electricity demand. Participating customers will receive compensation for the energy their Powerwalls discharge. "VPPs are a valuable resource for supporting grid reliability and an essential part of California's clean energy future. Our customers' home batteries offer a unique resource that can positively contribute to our state's electric grid and will become more significant as our customers continue to adopt clean energy technology. In collaborating with Tesla, we are further integrating behind-the-meter battery-based VPPs on the largest scale yet, helping to make customer resiliency technologies more accessible and continuing a long tradition at PG&E of actively integrating VPP resources into our energy supply portfolio," said PG&E's Aaron August, vice president, Business Development & Customer Engagement.

17:32 EDT Enthusiast Gaming announces two nominees from Greywood Investments to join board - Enthusiast Gaming announced that David Goldhill and Janny Lee, two nominees of Greywood Investments will join the company's board of directors and stand for election at the company's annual general meeting on July 19 at 10:00 a.m.

17:13 EDT General Dynamics awarded $280.11M Army contract - General Dynamics was awarded a $280.11M firm-fixed-price contract to procure trophy kits for the M1A2 SEPv2 and M1A2 SEPv3 Abrams Family of Vehicles. Bids were solicited via the internet with two received. Work locations and funding will be determined with each order, with an estimated completion date of July 7, 2027. U.S. Army Contracting Command is the contracting activity.

17:03 EDT Banc of California appoints Jagdeep Singh Sahota as Chief Payments Officer - Banc of California's wholly owned subsidiary, Banc of California, has hired Jagdeep Singh Sahota as Chief Payments Officer. In this newly created role, Sahota will be responsible for the development and oversight of the bank's strategic initiatives in payments, both its direct investment as well as related strategic partnerships. Sahota will report to Banc of California's COO, John Sotoodeh. Sahota has over 20 years of experience in the payments space and previously held senior leadership positions at NMI, JP Morgan Chase, Visa, Salesforce and PayPal. He has eight US patents and 23 global patent application filings to his name.

16:49 EDT KKR names Kathryn King Sudol as General Counsel, Sorkin as Chief Legal Officer - KKR & Co announced the appointment of Kathryn King Sudol as General Counsel of KKR. She will succeed David Sorkin who has served as General Counsel since 2007 and will become Chief Legal Officer of KKR. Both appointments are effective September 6, 2022. At the end of the first quarter of 2023, Ms. Sudol will assume the role of Chief Legal Officer, and Mr. Sorkin will become an Advisory Partner of KKR. Ms. Sudol joins from Simpson Thacher & Bartlett , where she is currently Global Co-Head of Mergers and Acquisitions. She is one of the world's leading corporate, M&A, and private equity lawyers, and has been a trusted advisor to corporate and private equity clients across a diverse range of industries in a variety of complex and high-profile transactions. During her 24-year career at STB, Ms. Sudol held numerous leadership roles, including as a longtime member of the firm's Executive Committee and as head of the firm's M&A practice in Asia from 2010 through 2018.

16:38 EDT Yamana Gold reports preliminary Q2 operating results - Yamana Gold reported preliminary Q2 operating results, with total gold equivalent ounce - GEO - production of 260,960 GEO. Gold production during Q2 was 232,542 ounces, with silver production of 2.36 million ounces. All-in sustaining costs are expected to be less than $1,090/oz. Cash and cash equivalents increased by more than $30M to a total quarter-end cash balance of over $328M from $298M at the end of Q1. This represents an improvement in cash flow generation of nearly $40 million compared to the first quarter of 2022. Year to date operating results position the company to achieve both its annual production and cost guidance. Year to date gold equivalent production has exceeded budget despite the gold to silver ratio being near an all-time high and significantly above the company's budget assumption for that ratio. The Phase 2 expansion at Jacobina continued to ramp-up during the quarter, with the mine achieving a sustained throughput rate of over 8,400 tpd in June. Yamana expects the throughput objective of 8,500 tpd to be achieved in July, establishing Jacobina's sustainable production profile at 230,000 ounces of gold per year. The company continues to advance preparations for its board-approved bulk sample program at its wholly-owned Wasamac project in the Abitibi-Temiscamingue Region of Quebec, Canada.

16:36 EDT Emergent BioSolutions, Ridgeback enter into agreement for Ebanga treatment - Emergent BioSolutions announced that it has entered into an agreement with Ridgeback Biotherapeutics, a biotechnology company focused on emerging infectious diseases, intended to create a collaboration to expand the availability of Ebanga. Under the terms of the contemplated collaboration, Emergent will be responsible for the manufacturing, sale, and distribution of Ebanga in the United States and Canada, and Ridgeback Bio will serve as the global access partner for Ebanga, ensuring it remains available to patients in endemic countries free of charge through Ridgeback Bio's compassionate use program. Ebanga was approved by the U.S. Food and Drug Administration in December 2020 for the treatment of Ebola. Ebanga is a monoclonal antibody with antiviral activity provided through a single injection and was developed for the treatment of Ebola by Ridgeback Bio under license from the National Institute of Allergy and Infectious Diseases. Ridgeback Bio provided funding and operational support for clinical testing, with additional funding received under contracts with the Biomedical Advanced Research and Development Authority for late-stage manufacturing and regulatory activities and ensured that the work necessary for FDA approval of Ebanga was completed. "This relationship with Ridgeback Bio builds on our strategic focus and deep expertise in developing and supplying medical countermeasures against serious health threats," said Robert G. Kramer, CEO of Emergent. "Ebanga is crucial in the ongoing fight to contain Ebola and we are excited about the future of this collaboration to create a healthier, more secure world."

16:33 EDT My Size granted Nasdaq listing extension to comply with minimum bid price - MySize recieved a notice from Nasdaq granting the company an additional 180 day period, or until January 2, 2023, to meet Nasdaq's minimum $1.00 bid price per share requirement. The company was first notified by Nasdaq of its failure to maintain a minimum bid price of $1.00 per share for 30 consecutive trading days under Nasdaq Listing Rules on January 3 was given until July 5 to regain compliance. The company submitted written request to the Nasdaq to afford it an additional 180-day compliance period to cure the deficiency.

16:31 EDT Voya Financial names Heather Lavallee CEO - Voya Financial announced that its board of directors has appointed Heather Lavallee, currently chief executive officer of Voya's Wealth Solutions business, to succeed Rodney O. Martin, Jr. as the company's CEO as part of Voya's planned succession process. Lavallee, who has been appointed Voya's president and CEO-elect, will become CEO on Jan. 1, 2023, when Martin, who also serves as chairman of Voya's board of directors, will assume the role of executive chairman. Lavallee has also been appointed to Voya's board of directors as of today. "On behalf of Voya's board of directors, I am delighted to announce Heather's appointment as our next CEO," said Martin. "As the CEO of our Wealth Solutions business - which delivered record earnings during 2021 - and in her prior business leadership roles, including leading what is now our Health Solutions business - where she significantly grew earnings during a five-year period - Heather has distinguished herself as an extraordinary executive focused on growth, innovation and culture. Working closely with me, our board and our entire management team, Heather has played a vital role in shaping and driving Voya's enterprise growth strategy - and is well-prepared to lead its continued execution and evolution going forward."

16:24 EDT Wentworth to go public through Kingswood Acquisition business combination - Kingswood Acquisition announced a definitive agreement to enter into a business combination with Wentworth Management Services. The transaction will enable Wentworth, a broker-dealer aggregator, to go public. As a result of the business combination, KWAC and Wentworth will become wholly-owned subsidiaries of Binah Capital, which will become a publicly traded company, subject to regulatory approvals. The combined entity is expected to encompass over 1,900 advisors, $25B in assets under management and over $285B in affiliated assets under management. The combined company will have a pro forma enterprise value of $208M. Wentworth owns and operates four broker-dealers, located in 535 offices in all 50 states. Affiliated financial advisors have the optionality to choose from operating models that include a hybrid open architecture platform, independent registered status, and a W2 advisor model. The business combination is projected to generate gross cash proceeds of approximately $30M, assuming no redemptions of cash in trust and an anticipated $15M capital raise, which will be used to pay transaction expenses and provide growth capital for the business. The implied pro forma equity value of the combined company is expected to be approximately $165M, with a pro forma enterprise value of approximately $208M. The transaction is expected to close in the fourth quarter of 2022, subject to customary closing requirements, including the approval of KWAC and Wentworth shareholders and regulatory review.

16:12 EDT Terreno Realty reports Q2 operating, investment and capital markets activity - Terreno Realty reported its operating, investment and capital markets activity for Q2. The company reported 97.9% quarter-end occupancy vs. prior quarter of 96.9% and prior year of 97.5%; 98.0% quarter-end same-store occupancy compared to prior quarter of 98.4% and prior year of 97.9%; 55.4% increase in cash rents on new and renewed leases; 42.8% increase year-to-date; $203.3M of acquisitions; $309.5M year-to-date; increased unsecured credit facility borrowing capacity by $150M to $400M; achieved LEED certification at 4151 West 108th Street; three buildings totaling 495,000 square feet LEED certified year-to-date. As of June 30, Terreno Realty Corporation owned 249 buildings aggregating approximately 15.1 million square feet and 42 improved land parcels consisting of approximately 147.7 acres. In addition, Terreno Realty Corporation had four properties under redevelopment that upon completion will consist of three buildings aggregating approximately 334,000 square feet and two improved land parcels of approximately 12.1 acres: During Q2, Terreno acquired ten properties consisting of ten buildings containing approximately 330,000 square feet and five improved land parcels of approximately 19.5 acres for an aggregate purchase price of approximately $203.3M. Year-to-date, Terreno Realty Corporation acquired 13 properties consisting of 14 buildings containing approximately 766,000 square feet and seven improved land parcels of approximately 27.4 acres for an aggregate purchase price of $309.5M. During Q2, Terreno Realty issued 27,087 shares of common stock with a weighted average offering price of $76.03 per share, receiving gross proceeds of $2.1M under the company's at-the-market equity offering program. Terreno did not repurchase any shares of common stock pursuant to the company's share repurchase authorization.

16:11 EDT Marathon Digital produces 707 self-mined bitcoin in Q2 - Marathon Digital Holdings published unaudited bitcoin production and miner installation updates for June. The company produced 707 self-mined bitcoin during Q2, an 8% increase from 654 bitcoin mined in Q2 2021. Q2 2022 bitcoin production was significantly impacted by: The energization delays in Texas; maintenance to the power generating facility in Hardin, Montana during April and May and a severe storm that passed through the Hardin region damaging the power generating facility that supplies Marathon's miners in the region with power and causing Marathon's miners in Montana to go offline. Due to the storm, current operating mining fleet was reduced to approximately 6,300 active miners producing approximately 0.7 EH/s and BTC production was significantly reduced in June with 140 self-mined bitcoin produced during the month. Year-to-date through June 30, the company produced 1,966 bitcoin, a 132% increase over the same time period in the prior year. The Total number of miners installed and awaiting energization at Texas facilities increased to 29,640 miners. Total bitcoin holdings are 10,055 BTC with a fair market value of $198.9M. Given the elimination of the investment fund, all of this bitcoin is held directly as digital currencies on the balance sheet. Cash on hand was approximately $88.7M and total liquidity, defined as unrestricted cash and available credit facilities, was approximately $153.7M. "In the second quarter, we continued to work through several operational obstacles as we progressed with installing miners in Texas in preparation of energization," said Fred Thiel, Marathon's chairman and CEO. "In April and May, our bitcoin production was impacted by ongoing maintenance issues at the power generating facility in Hardin, MT that supplies our Hardin-based miners with power. On June 11, the situation was exacerbated by a severe storm that passed through the region, damaging the power plant's cooling towers and leaving our 30,000 miners in the region without power. According to the most recent reports, these miners, which represent over 75% of our active fleet, appear to be mostly undamaged by the storm. The ground crew at Hardin continues to make progress as they work to bring the power plant and our miners back online in a reduced capacity."

14:48 EDT Truth Social denies Donald Trump left board of Trump Media - The official account of Truth Social posted the following on its platform: "Contrary to an 'exclusive' fake news story filed by a reporter who is incapable of understanding state business records, Donald Trump remains on the board of Trump Media and Technology Group. In fact, the reporter acknowledges that Trump's title is 'chairman,' but apparently has no clue what a chairman presides over. Hopefully this helps clarify things." Earlier, Chris Anderson of the Sarasota Herald-Tribune had reported that the former president had left the board of Trump Media and Technology Group, which is in the process of merging with blank-check company Digital World Acquisitions Corp. Reference Link

13:40 EDT Cygnus to vote for Swann, Hart as Preferred Trustees of Pennsylvania REIT - Cygnus Capital, a long-term shareholder of beneficial interests and preferred shares of Pennsylvania Real Estate Investment Trust, issued a statement regarding Cygnus' voting intentions with respect to the 2022 Annual Meeting of Shareholders, originally held on June 2, 2022, and adjourned to 11:00 a.m. Eastern Time on August 2, 2022. Holders of record as of the close of business on April 11, 2022, the record date for the Annual Meeting, of PEI's 7.375% Series B Cumulative Redeemable Perpetual Preferred Shares, 7.20% Series C Cumulative Redeemable Perpetual Preferred Shares and 6.875% Series D Cumulative Redeemable Perpetual Preferred Shares have the right to elect two trustees to PEI's Board of Trustees since the Trust has not paid cash dividends on its outstanding preferred shares for six quarters. The only item on the agenda for the reconvened Annual Meeting is the election of the Preferred Trustees. Cygnus said, "Cygnus has nominated Christopher Swann, and Kenneth Hart has nominated himself, for election to serve as the Preferred Trustees at the Annual Meeting. Each of Messrs. Swann and Hart will be elected as Preferred Trustees by a plurality of the votes cast. Cygnus believes that a quorum, as defined in the Trust's governing documents, was achieved at the originally convened June 2, 2022 date of the Annual Meeting. Unfortunately, PEI has adopted a position which Cygnus believes is inconsistent with the plain language set forth in the Trust's governing documents, asserting that a majority of the outstanding Preferred Shares is needed to constitute a quorum before the proposal to elect Messrs. Swann and Hart as Preferred Trustees can be considered. Cygnus has repeatedly raised to the Trust's management that its interpretation of the quorum requirement has deprived holders of Preferred Shares of the Board representation to which they are entitled. Cygnus has also expressed grave concerns regarding the minimal effort being spent by the Trust to achieve this purported quorum requirement. While Cygnus disagrees with the Trust's position, Cygnus is nonetheless taking this opportunity to inform holders of Preferred Shares of their right to representation on the Board and to make clear its voting intentions with respect to the Annual Meeting. We intend to vote "FOR" the election of Messrs. Swann and Hart as Preferred Trustees because Cygnus believes PEI has a limited window to put its financial affairs in order and representation on the Board by holders of Preferred Shares is a necessary and important step in that process. PEI has significant near term debt maturities that must be addressed in order to protect the economic interests of shareholders. Specifically, progress must be made in meeting the debt covenants under the Fashion District Partnership Loan Agreement as well PEI's other credit agreements which have deadlines in January 2023 and December 2022, respectively. Holders of the Preferred Shares are entitled to representation as these deadlines loom. Cygnus believes the Preferred Trustees have the requisite skillsets and owner mindset to add significant value to the Board during these difficult times."

12:46 EDT Meta to let VR headset users log in without Facebook account - Meta introduced new Meta accounts, a new way for people to log into their VR headsets that doesn't require a Facebook account. "When we announced that we would start requiring people to log into Meta Quest using a Facebook account, we received a lot of feedback from the Quest community," the company said. "We took that feedback into account as we designed a new Meta account structure that gives people flexibility and control." Reference Link

12:00 EDT Direxion Daily Semiconductor Bear 3X Shares falls -10.9% - Direxion Daily Semiconductor Bear 3X Shares is down -10.9%, or -$7.68 to $62.80.

12:00 EDT ProShares UltraShort Bloomberg Natural Gas falls -24.5% - ProShares UltraShort Bloomberg Natural Gas is down -24.5%, or -$9.86 to $30.36.

12:00 EDT Crescent Point Energy rises 13.6% - Crescent Point Energy is up 13.6%, or 87c to $7.27.

11:33 EDT Veru off highs after short makes case authorization has 'zero chance' - Adam Feuerstein, a noted biotech reporter for STAT News, highlighted earlier a tweet thread from Twitter account "Midwestern Hedgie," who acknowledges being short "a little bit" of shares of Veru previously and to having "added aggressively today to our short position." The stock was higher in the pre-market and extending into this morning after Jefferies predicted that yesterday morning's COVID-19 data would lead to an Emergency Use Authorization, or EUA, for Veru by the FDA in 30 days. In his tweets laying out a short thesis on Veru, "Midwestern Hedgie" stated in part: "17% of the patients in the sabizabulin group died, and 35% of the patients in the placebo group died. It's EXACTLY what you'd expect if deaths were being caused by Covid + hypoxemia (which they are), and sabizabulin was doing absolutely nothing... IMO (as an M.D. who taught evidence-based medicine to colleagues & residents) this drug has zero chance of an EUA." In late morning trading, Veru shares remain up $1.06, or 8%, to $14.08, though off their earlier highs. Reference Link

10:59 EDT Nio, Xpeng and Li shares rise as China considers EV tax break extension - Shares of Chinese EV makers Li Auto (LI), Xpeng (XEPV) and NIO (NIO) are on the rise on Thursday after the Chinese Ministry of Commerce issued a notice indicating support for sales of new and used cars, and saying that it would consider extending a tax break for electric vehicles and build more charging stations. The plans, announced by the Ministry of Commerce as part of a joint statement with 16 other departments, include: "Support the consumption of new energy vehicles, and study the issue of extension after the expiration of the new energy vehicle purchase tax exemption policy... Actively support the construction of charging facilities, accelerate the construction of charging facilities in residential communities, parking lots, gas stations, expressway service areas, passenger and freight hubs, etc., and guide charging pile operators to appropriately reduce charging service fees." Reference Link

10:27 EDT Intergrated Media Technology Ltd trading resumes

10:20 EDT Volkswagen says 'PowerCo' to invest more than EUR 20B in 'battery offensive' - Volkswagen announced that "to kick off its battery offensive," the Group broke the ground for its first cell factory in Salzgitter today in the presence of German Chancellor Olaf Scholz. Production will start in 2025. With immediate effect, responsibility for VW's global battery business is to be held by the newly created company "PowerCo". In addition to cell production, the new company will be responsible for activities along the entire battery value chain. Up to 2030, PowerCo is to invest more than EUR 20B together with partners in the development of the business area, to generate annual sales in excess of EUR 20B and to employ up to 20,000 people in Europe, the company added. Herbert Diess, CEO of Volkswagen AG, said: "Today we are not only laying a foundation stone but also marking a strategic milestone. The battery cell business is one of the cornerstones of our NEW AUTO strategy which will make Volkswagen a leading provider of the sustainable, software-driven mobility of tomorrow. Establishing our own cell factory is a megaproject in technical and economic terms. It shows that we are bringing the leading-edge technology of the future to Germany!" Reference Link

10:03 EDT First Northwest Bancorp makes investment in Meriwether Group - First Northwest Bancorp, parent company of First Fed Bank, announced a strategic investment in Meriwether Group, a firm providing accelerator, financial, and family office services. The equity investment formalizes a partnership that has developed in recent years. First Fed and Meriwether Group have partnered to serve a number of business clients including BILLY Footwear, Tutta Bella, and Seattle Sun Tan.

10:00 EDT Direxion Daily Semiconductor Bear 3X Shares falls -11.0% - Direxion Daily Semiconductor Bear 3X Shares is down -11.0%, or -$7.78 to $62.70.

10:00 EDT Annovis Bio rises 11.0% - Annovis Bio is up 11.0%, or $1.46 to $14.72.

10:00 EDT Grove Collaborative rises 38.5% - Grove Collaborative is up 38.5%, or $1.54 to $5.54.

09:47 EDT Duckhorn Portfolio falls -8.4% - Duckhorn Portfolio is down -8.4%, or -$1.74 to $18.99.

09:47 EDT Tenneco says Jim Voss to succed Brian Kesseler as CEO - On February 22, Tenneco (TEN) entered into an Agreement and Plan of Merger by and among Tenneco, Pegasus Holdings III, LLC, a Delaware limited liability company, and Pegasus Merger Co., a Delaware corporation and wholly owned subsidiary of Parent, pursuant to which among other things, and subject to the terms and conditions set forth therein, Merger Sub will be merged with and into Tenneco, with Tenneco surviving as a wholly owned subsidiary of Parent. Parent and Merger Sub are affiliates of Apollo Global Management (APO). On July 7, in a regulatory filing, Brian J. Kesseler, the CEO of Tenneco, confirmed that, subject to and effective only upon consummation of the Merger, Kesseler intends to depart as Tenneco's CEO. Parent and Merger Sub have advised Tenneco that they intend to appoint Jim Voss as Tenneco's CEO effective upon the consummation of the Merger and Kesseler's departure.

09:47 EDT Grove Collaborative rises 11.2% - Grove Collaborative is up 11.2%, or 45c to $4.45.

09:47 EDT Annovis Bio rises 12.5% - Annovis Bio is up 12.5%, or $1.66 to $14.92.

09:40 EDT Ebix says Delhi Court blocks publishing of Hindenburg short report in India - Ebix announced that the Delhi Court has blocked the publishing of the Hindenburg Report in India, with immediate effect. Further, the Court, via its Order, has directed Google and Twitter, Inc to take down relevant URLs from the Indian domain pertaining to the Hindenburg Report. EbixCash had filed a suit before the Tis Hazari Court, Delhi against Hindenburg and its founders, Google, Twitter Inc. along with other parties for permanent, prohibitory and mandatory injunction along with defamation and damages in relation to the Hindenburg Report. While providing a detailed rebuttal with proof to the Court, the Company provided the Court with audit reports from India's financial regulatory body and two independent auditors, for the last 3 years. The Court by its order dated July 5, 2022 restrained the Defendants from publishing the Hindenburg Report till the final disposal of the Suit. While Hindenberg chose not to be present at the hearings, Google LLC and Twitter, Inc were represented by their respective counsels at the hearing.

09:32 EDT Christian Blind Mission implements OpenText's Exstream software - OpenText announced Christian Blind Mission has implemented its Customer Communications Management software, OpenText Exstream, to personalize and automate hundreds of thousands of essential donor communications, increasing efficiency and improving donor relations around the world.

09:22 EDT Enterprise Products increases quarterly cash dividend to 47.5c per share - Enterprise Products announced that the board of directors of its general partner declared the quarterly cash distribution paid to limited partners holding Enterprise common units with respect to the second quarter of 2022 of 47,5c per unit, or $1.90 per unit on an annualized basis. The quarterly distribution will be paid Friday, August 12 to common unitholders of record as of the close of business Friday, July 29. This distribution represents a 5.6% increase over the distribution declared with regard to the second quarter of 2021.

09:21 EDT Crackle Plus says 'In the Vault' garners over 3.4M views since June 1 - Crackle Plus announced that the series In the Vault has garnered over 3.4 million views since its premiere June 1, making it one of the most-watched new shows on Crackle.

09:20 EDT LiveOne expands emerging talent program, launching 'OneRising' - LiveOne announced the launch of its new emerging artists program, OneRising, breaking up-and-coming talent across the music landscape. Additionally, LiveOne has rolled-out the OneRising Radio station across its platform that offers artists promotional opportunities on par with some of the world's biggest talent. The first wave of artists includes: Le Coco Ramos; Austin George; Lou Ridley; and Skeez. "LiveOne has a rich history of breaking new talent to global audiences," said Josh Hallbauer, Head of Music Publishing of LiveOne. "OneRising will offer today's brightest new artists a platform to showcase their music and content across our flywheel, while opening new opportunities to connect with their fans and LiveOne's worldwide members. We are thrilled to be on this journey with them."

09:18 EDT Quest Diagnostics partners with CDC to extend $0 out-of-pocket COVID-19 testing - Quest Diagnostics announced it is now a participating partner in the Centers for Disease Control and Prevention's, CDC, Increasing Community Access to Testing, ICATT, for COVID-19 program, which is designed to support free COVID-19 laboratory testing for patients in U.S. communities that have been disproportionately affected by the pandemic. Through the program, Quest will expand access to $0 out-of-pocket COVID-19 testing to uninsured individuals who qualify at approximately 1,200 of the company's 2,100 patient service centers. CDC chose Quest following a competitive bid. Financial terms were not disclosed.

09:17 EDT Xenetic enters clinical manufacturing agreement with Catalent - Xenetic Biosciences announced it has entered into a manufacturing agreement with Catalent Pharma Solutions, which will include cGMP manufacturing for the Company's recombinant protein, Human DNase I. The Company is working toward its planned first-in-human study to evaluate DNase combined with immune checkpoint inhibitors or chemotherapy.

09:14 EDT NextNav enters partnership with VOS Systems - NextNav has partnered with VOS Systems to bring vertical location capabilities to its CoRe product line through NextNav's Pinnacle service. Together, the two companies will spearhead the first connected worker solution to have vertical location capabilities, providing increased employee safety, improving workplace efficiency, and allowing for faster emergency response to affected workers. "At NextNav, we're enhancing location data to the three-dimensional world we live in," said Dan Hight, Vice President of Business Development and Partnerships at NextNav. "By bringing our Pinnacle service to VOS Systems' technology, we're helping businesses understand what floor their workers are on, improving safety and communication. Together, we're setting a path forward for a safer and more efficient workplace for personnel across several industries from construction to education."

09:10 EDT Biora Therapeutics' platform completes second device performance study in humans - Biora Therapeutics announced topline results from its recently completed study PM-611: Safety and Functionality Assessment of the Drug Delivery System Capsule in humans. The study assessed whether the autonomous location functionality of the ingestible devices was impacted by a fed state as compared to a fasted state. The study demonstrated that all capsules were safely ingested and exited the body naturally, with no serious adverse events reported. Having now completed two studies in humans, Biora expects to report on its third human study during Q3. No drug was administered during the study.

09:08 EDT Luokung granted extension to meet Nasdaq minimum bid price requirement - Luokung Technology announced that on July 6, 2022, the Company received an additional 180 calendar day extension from Nasdaq's Listing Qualifications Department to meet Nasdaq's continuing listing requirements by maintaining a minimum bid price per share of $1.00 for a minimum of 10 consecutive trading days. The Company now has until January 2, 2023 to regain compliance. Nasdaq's extension notice has no immediate effect on the continued listing status of the Company's ordinary shares on Nasdaq. If at any time before January 2, 2023, the bid price of the Company's ordinary shares closes at or above $1.00 per share for a minimum of 10 consecutive trading days, the Company will regain compliance with the Nasdaq Listing Rules, and the matter will be closed. The Company was first notified by Nasdaq of its failure to maintain a minimum bid price of $1.00 per share for 30 consecutive trading days under Nasdaq Listing Rules 5550(a)(2) and 5810(c)(3)(A) on January 3, 2022, and was given until July 5, 2022 to regain compliance. If the Company does not meet the minimum bid requirement during the additional 180-day extension, Nasdaq will provide written notification to the Company that its ordinary shares will be subject to delisting.

09:08 EDT Tecogen receives order for three Tecochill chillers for Connecticut High School - Tecogen received an order for three 400 ton Tecochill chiller systems by a municipality in Connecticut. The chillers will provide seasonal cooling at a high school in southwestern Connecticut with the free hot water used for dehumidification. The 1,200 tons of Tecochill chillers replace a different manufacturer's aging and inefficient absorption chiller system and will reduce carbon emissions by more than 1,100 tons per year compared to the existing cooling plant. It is anticipated that the municipality will enter into a long-term service and maintenance agreement for the three new chillers.

09:06 EDT Taboola signs two-year deal with MediaNews for integrated feed - Taboola announced a new two-year deal with MediaNews Group. The agreement also extends Taboola's multi-year partnership with Tribune Publishing to 10 years. Tribune Publishing was purchased by MediaNews Group's majority owner, Alden Global Capital, in 2021. Under the agreement, MediaNews Group will incorporate Taboola Feed, an integrated feed that provides readers with personalized content. Tribune Publishing has previously leveraged Taboola Feed across its network of sites including the Chicago Tribune, the Baltimore Sun, the Orlando Sentinel, Virginia's Daily Press and more. Taboola will now be MediaNews Group's new partner for all sites including LA Daily News, Colorado Daily, the Boston Herald and the Saratogian, among others.

09:05 EDT CME Group announces the addition of six new contracts - CME Group announced plans to expand its suite of Sector futures with the addition of six new contracts on August 8, pending regulatory review. These new contracts will include: E-mini S&P Regional Banks Select Industry futures; E-mini S&P Insurance Select Industry futures; E-mini S&P Biotechnology Select Industry futures; E-mini S&P Oil & Gas Exploration and Production Select Industry futures; E-mini S&P Retail Select Industry futures; and E-mini PHLX Semiconductor Sector Index futures. "We continue to see strong market demand for liquid, cost-effective and capital-efficient tools to track the same underlying indices as some of the most popular ETFs," said Tim McCourt, CME Group Global Head of Equity and FX Products. "These new contracts will provide more opportunities and versatility in managing sector exposure and will complement the growing liquidity pool of our existing Sector futures product suite, which cover more than 10 S&P Select Sectors, as well includes Dow Jones US Real Estate and Nasdaq Biotech futures, giving clients more tools to meet their trading needs."

09:03 EDT PictureTel Corporation receives certification for IoT Radio Module in Europe - PictureTel announced receipt of the Declaration of Conformity in Europe for their IoT Radio Module.

09:03 EDT Tetra Tech acquires The Integration Group of Americas, no terms - Tetra Tech announced that it has expanded its digital water practice with the acquisition of The Integration Group of Americas TIGA, an industry leader in process automation and systems integration solutions, including customized software and platform SaaS/PaaS applications, advanced data analytics, cloud data integration, and platform virtualization. TIGA expands the company's digital water practice with industry-leading software engineers, digital automation integrators and advanced data analytics consultants. "Tetra Tech uses our Leading with Science approach and the suite of Tetra Tech Delta technologies to provide digital solutions for our clients that generate value by leveraging data analytics and systems integration," said Dan Batrack, Tetra Tech Chairman and CEO. "The addition of TIGA enables us to further expand our high-end digital consulting and platform solutions across water, environmental, and energy sectors." John Miller, TIGA President, said, "Solving complex challenges related to water, energy, and sustainable infrastructure by leveraging data analytics is a critical need for our clients. By joining Tetra Tech, we will provide industry-leading control system integration and digital transformation services to an expanded client base while simultaneously providing new opportunities for our employees." The terms of the acquisition were not disclosed. TIGA is joining Tetra Tech's Government Services Group.

09:02 EDT KVH Industries introduces KVH ONE hybrid network - KVH Industries introduces the KVH ONE hybrid network and TracNet terminals for fast, reliable connectivity at sea and at the dock. The TracNet H30, H60, and H90 terminals feature satellite, cellular, and Wi-Fi technology under one dome, with intelligent, automatic switching based on availability, cost, and quality of data connection to continually deliver the best performance.

08:54 EDT SG Blocks partnership Clarity Mobile Venture signs extension with LAX - SG Blocks announced that Clarity Mobile Venture, a partnership with Clarity Lab Solutions, is extending its contract with Los Angeles International Airport LAX for COVID-19 testing. COVID-19 testing has been successfully operational since November of 2020. The lab has seen thousands of visitors who are looking for a convenient and safe testing option prior to flying. The lab offers Standard and Rapid PCR tests, in addition to Antigen tests. The facility is located across the street from Terminal 6, and results are delivered electronically. SG Blocks has the capability to relocate the licensed CLIA lab as appropriate, should a time come when services are no longer needed at LAX. The Company continues to review potential relocation sites and partners.

08:45 EDT CLPS announces new generation of loan management system development - CLPS Incorporation announced the development of a new generation of loan management system, a product intended for small and medium-sized banking institutions. CLPS plans to launch the loan management system in Hong Kong and Southeast Asia region in 2023. "Digital products and services offered by traditional banks should be improved in Hong Kong, as it actively promotes technological innovation in the banking sector," said Raymond Lin, Chief Executive Officer of CLPS. "We hope to take this as an entry point to further invest in product development and help our clients in building distinctive businesses to remain competitive in the future of digital transformation."

08:43 EDT Quisitive Technology appoints Amy Brandt to board of directors - Quisitive Technology Solutions has appointed Amy Brandt to its Board of Directors, effective June 29, 2022. Brandt replaces Vijay Jog, who has served on the board since 2019. With Brandt's appointment, Quisitive's Board composition remains at five total directors, four of whom are independent. She is currently an Operating Executive Director at Serent Capital, a leading lower-middle market private equity firm investing in high growth service and technology businesses.

08:41 EDT Alvotech initiates patient study for AVT06 - Alvotech announced the initiation of the company's confirmatory clinical study for AVT06, a biosimilar candidate to Eylea. The objective of the study is to compare AVT06 and Eylea in terms of efficacy, safety, and immunogenicity in adult patients with neovascular age-related macular degeneration. The study is a randomized, double-masked, parallel-group, multicenter, therapeutic equivalence study, and is expected to enroll approximately 444 participants globally. The study's primary endpoint is the change in best corrected visual acuity from baseline to week 8.

08:39 EDT Grove's Adtech platform adds new partners within financial industry - Grove's wholly owned Adtech platform, Interactive Offers, continues its expansion into eCommerce with the addition of new partners within the financial industry using its SaaS advertising platform. The company has now partnered with Outbrain, ZeroHedge, StreetAuthority, and InvestingDaily, who will now utilize Interactive's SaaS advertising technology to monetize their current database as well as bring in new, targeted leads/customers. Interactive Offers provides a comprehensive programmatic ad tech solution. The company is scaling its click-to-opt-in program that can be used in email advertising, display advertising, and even on transactional confirmation pages.

08:39 EDT Taseko Mines updates status of copper price protection program - Taseko Mines announces that copper collars for the first half of 2023 have been acquired to secure a minimum copper price of $3.75 per pound and a ceiling price of $4.72 per pound for 30M pounds of copper. This collar was purchased in mid-June when the price of copper was approximately $4.20 per pound. These new collars extend the price protection that is in place for the current year, which secures a minimum copper price of $4.00 per pound for 42M pounds over the second half of 2022. At recent copper prices, the current outstanding contracts will provide approximately C$45M of additional cash flow over the next year. Stuart McDonald, Taseko's President and CEO, commented, "We have consistently used a price protection strategy for over ten years to protect our balance sheet from sudden downward moves in the copper price, like we have seen over the last month. With this price protection in place, and with the improvements in head grades and copper production from Gibraltar that we expect in the second half of this year, our balance sheet will remain strong as we prepare for construction of our Florence Copper Project," concluded McDonald.

08:37 EDT Dogness International announces strategic partnership with Xiuhu - Dogness announced a new retail distribution partnership with Xiuhu, which operates over 200 pet stores in China. Under the new strategic cooperation, Xiuhu will feature Dogness' products in their premium pet specialty stores nationwide. The companies plan to work together to jointly explore and develop successful retail operations and other potential business areas. They also plan to jointly promote the development of sustainable and branded pet retail business to achieve mutual benefit for both companies. Silong Chen, Chairman and Chief Executive Officer of Dogness, commented, "The investments we have made in the development of our intelligent products are driving more and more retail partners to do business with Dogness, as they seek innovative products that can meet the evolving needs of pet parents in the digital age. As one of world's most successful pet retail chains, Xiuhu is a trusted and valued source for premium pet supplies and we are proud to join forces. Our strategic cooperation represents the latest significant expansion of Dogness' retail distribution network, as we bring the wonderful experience of our technology enhanced products to pet owners everywhere and work to accelerate our company's growth."

08:36 EDT AudioEye selected by Celerant as digital accessibility partner - AudioEye announced that Celerant has selected AudioEye as their digital accessibility technology and services provider. The partnership aims to help customers across Celerant's diverse portfolio of retailers ensure their digital experiences are equally accessible to all users, regardless of ability. Celerant customers will be able to leverage the power of AudioEye's patented accessibility technology to find and fix the most common web accessibility issues, allowing them to acquire new customers by providing accessible customer experiences. "AudioEye's comprehensive solution aligns with Celerant's combination of advanced technology and human expertise and will provide Celerant's customers, and Celerant themselves, with new growth opportunities," said David Moradi, CEO of AudioEye. "Our team is proud to have been selected by Celerant to be their digital accessibility partner."

08:35 EDT The Very Good Food announces eastern US retail expansion with The Giant Company - The Very Good Food Company announces increased U.S. retail expansion via a new agreement with The Giant Company. With Giant's presence throughout Pennsylvania, Maryland, Virginia, and West Virginia as well as online shopping and delivery to New Jersey, this retail distribution significantly expands VERY GOOD'S product availability on the U.S. Eastern Seaboard. VERY GOOD's CEO, Parimal Rana, commented on the Company's new distribution with Giant. "This is yet another win for our team in line with our refocused strategy of expanding our retail footprint Giant is known as a forward-thinking company and has a history of successfully introducing innovative brands to consumers. Their inclusion of our Meatballs, Cajun & Bratwurst sausages, and The Stuffed Beast products is yet another opportunity for us to gain new customer adoption. With our natural and clean plant-based ingredients, we are confident in our products' ability to perform well within Giant's HNO venue".

08:34 EDT BRP entered into definitive agreement to acquire Great Wall Motor Austria - BRP (DOOO) announced that it has entered into a definitive agreement to acquire Great Wall Motor Austria, a subsidiary of Great Wall Motor (GWLLF) based in Baoding, China. This leading EV R&D centre based in Kottingbrunn, Austria, specializes in e-drive systems and transmissions and currently employs highly skilled individuals who will receive ongoing employment as part of this agreement. "We look forward to welcoming the 53 very qualified and experienced engineers, technicians and professionals as we continue reinforcing our EV expertise required to deploy our ambitious strategy. This acquisition will further strengthen our know-how in e-motor, inverter hardware and software development", said Thomas Uhr, Chief Technology Officer of BRP.

08:33 EDT Milestone Scientific begins sales of CompuFlo disposables to California center - Milestone Scientific reported that it has commenced sales of its CompuFlo Epidural disposables to a medical center in Southern California. This medical center belongs to one of the nation's largest not-for-profit healthcare systems serving over 10 million members, with more than 100,000 babies delivered each year across multiple states.

08:30 EDT Galmed reports anti-fibrotic effects of Aramchol in lung fibrosis model - Galmed Pharmaceuticals announced results showing significant effects of Aramchol in pre-clinical model of both lung and gastrointestinal, GI, fibrosis. Treatment with Aramchol resulted in statistically significant fibrosis improvement in a validated bleomycin model of lung fibrosis, comparable to Pirfenidone which is the gold standard treatment. Findings were seen across all important indicators for the severity of fibrosis. Statistically significant improvements were also demonstrated in a validated DSS model of inflammatory bowel disease, IBD. Dextran sulfate sodium, DSS, induced colitis model is widely used because of its similarities with human ulcerative colitis. Aramchol was found to be the most effective compound tested. Control groups included 5-ASA and local steroids which are the gold standards for current treatment. "I am excited with today's news showing that established data about the role of SCD1 in lipid metabolism and fibrosis in the liver, is being replicated in other organs. Today we show that Aramchol's effect is evident in other organs, such as lung and gastrointestinal tract and may be as substantial as the one observed in the liver. The new findings, together with the robust anti-fibrotic effects demonstrated in clinical studies of patients with NASH and advanced fibrosis could potentially enable Galmed to quickly transition to Phase 2/3 clinical studies with Aramchol in indications with unmet need and faster development pathways." stated Allen Baharaff co-founder, President and CEO of Galmed.

08:23 EDT Kiromic BioPharma completes cGMP manufacturing facility construction in Houston - Kiromic BioPharma announced the completion of construction on its expanded current good manufacturing practice, or cGMP, manufacturing facility in Houston. This milestone was accomplished within the timeline established by the company, specifically June 30. The expanded facility located at Kiromic's headquarters is one of the conditions required for the company to begin the activation of its cell therapy clinical trial for the Deltacel product candidate by the end of this year. The completion also addresses a component in the clinical hold communication the company received from the FDA in June. The expanded 34,000-square-foot facility includes flexible cellular therapy and viral vector suites, a dedicated cGMP microbiology lab, a dedicated cGMP quality control lab, a research and development laboratory, and an FDA Code of Federal Regulations compliant vivarium.

08:21 EDT Nitches enters final phase of Miles Davis clothing collection with artist Fe - Nitches announced it's entering the final phase of its Miles Davis clothing collaboration with Voodo Fe, a multimedia artist and producer with over 8,000 works of art. VooDo Fe has a licensing agreement with the Miles Davis family to create an exclusive collection of streetwear items that celebrate the life and work of one the world's greatest musicians. Fe approved the clothing samples and is already planning to expand the initial product run. "The collection is top-of-the-line and very distinctive, making the items a must-have for fans of the great Miles Davis," said John Morgan, Nitches' CEO. "VooDo Fe's creativity and imagination is what led to this -one-of-kind clothing line and could even lead to clothing with an embedded NFT collection in the future."

08:19 EDT Eyenovia appoints Ellen Strahlman, Ram Palanki to board of directors - Eyenovia (EYEN) announced that it has appointed Dr. Ellen Strahlman and Dr. Ram Palanki as new and independent members of its Board of Directors. With these appointments, the Eyenovia Board will expand to eight seats, from six currently. Strahlman served as Executive Vice President, Research & Development and Chief Medical Officer of Becton, Dickinson and Company (BDX), a leading global medical technology company, from 2013 until her retirement in 2018. Dr. Strahlman will serve on Eyenovia's compensation and audit committees. Dr. Ram Palanki currently serves as Executive Vice President of Commercial Strategy & Operations at REGENXBIO (RGNX), a leader in AAV gene therapy, and is responsible for the planning, execution, and commercialization of their pipeline across the ophthalmology, central nervous system, and neuromuscular disease franchises. Dr. Palanki will serve on Eyenovia's compensation committee.

08:16 EDT GE Gas Power to acquire Nexus Controls from Baker Hughes - GE (GE) announced that its Gas Power business intends to acquire Nexus Controls, a Baker Hughes (BKR) business, specializing in aftermarket control system upgrades and controls field services to "create a single, world-class full-service controls business within GE." GE said: "Following deal closure, the proposed integrated business would develop the future of GE's proprietary Mark Vle controls systems platform for customers, design retrofit and modernization offerings, and streamline and improve the delivery and service of controls in the power generation space." Scott Strazik, CEO of GE's energy business portfolio, added: "The proposed acquisition of Nexus Controls from Baker Hughes is expected to strengthen our quality, service, and delivery of a world-class controls experience for our customer's assets. Integrating GE's controls capabilities with those from Nexus Controls would re-position GE as a global leader in controls products, engineering, and lifecycle services-ultimately providing new value and innovation for our customers and aligning world-class controls talent into a single organization." The financial terms of the acquisition are not being disclosed.

08:12 EDT Organogenesis receives FDA 510(k) clearance for PuraPly MZ - Organogenesis has received FDA 510(k) clearance for the PuraPly Micronized Wound Matrix, according to a notice posted on the FDA's website. Reference Link

08:12 EDT S&P Global Commodity Insights launches new daily price assessments of ammonia - S&P Global Commodity Insights, a division of S&P Global, has launched daily price assessments for ammonia through its Fertecon brand. These new, daily ammonia assessments add to Fertecon's long-established weekly price assessments and provide greater price transparency to a burgeoning marketplace and increasingly important low-carbon fuel source. "The drive toward lower-carbon fuel sources has increased the demand for pricing and transparency in the ammonia markets," said Ian Dudden, Global Pricing Director, Agriculture, S&P Global Commodity Insights. "Our new Fertecon daily price assessments will further illuminate ammonia values in what can be a volatile market. They augment a pre-existing suite of conventional and low-carbon ammonia price references from Fertecon and Platts that shed insight on weekly, daily and forward-curve values." The new Fertecon daily price assessments reflect values for four regions - Northwest Europe, the Middle East, the Far East, and the U.S. Gulf Coast/Tampa Bay. The daily assessments, launched on July 1, 2022, will be in addition to Fertecon's weekly assessments in the Ammonia Report and the weekly AESI Update and will be available to all subscribers of the weekly Ammonia Report.

08:10 EDT Sabre accelerates NDC rollout offers with Qatar Airways - Sabre has successfully integrated IATA New Distribution Capability, NDC, content from Qatar Airways, QR, to its global distribution system, GDS. After a pilot phase with agency customers in Australia and Sweden, the offers of Qatar's flag carrier will now be rolled out successively to travel agencies across the globe starting on July 7, 2022. Travel agencies will be able to shop, book, and manage NDC offers from Qatar Airways. Access to Qatar's content will be available through Sabre Red 360, Sabre's agency point-of-sale tool, as well as its NDC-enabled Offer and Order Application Programming Interfaces. With Qatar Airways' extensive network of destinations, access to the carrier's unique NDC content is expected to be relevant to travel buyers across the globe in the post-COVID-19 recovery period and beyond.

08:09 EDT Akari Therapeutics reports first completed treatment in Phase 3 nomacopan trial - Akari Therapeutics announced that a patient has completed the course of investigational nomacopan treatment in the open-label, multi-center Phase III Part A clinical trial in pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy - HSCT-TMA -. Nomacopan is a bispecific recombinant inhibitor of complement C5 and leukotriene B4. Three patients with severe HSCT-TMA have been enrolled in the clinical trial. Dosing has begun in the third patient. Nomacopan was granted Orphan Drug and Fast Track designations by the FDA for pediatric HSCT-TMA. Data from the Phase III Part A study of nomacopan in HSCT-TMA will inform the pivotal Phase III Part B study that will be the basis for potential regulatory submissions in the U.S. and Europe.The mortality rate in patients who develop severe transplant-related TMAs is 80%. Currently, there are no approved treatment options in the U.S. or Europe. Sites are open and recruiting in the U.S, U.K., and Poland for the Phase III Part A clinical trial of investigational nomacopan in pediatric patients who have undergone allogeneic or autologous HSCT and develop HSCT-TMA within a year of transplant. Patient dosing is underway in the multi-center, open-label study that has a recruitment goal of seven pediatric patients over six months old.

08:08 EDT TD Synnex announces new partnership with APARAVI - APARAVI announced a new partnership with TD SYNNEX, a global IT distributor and solutions aggregator formed through the merger of Tech Data and Synnex. As a trusted disrupter in unstructured data management, this partnership will help companies take control of their data. "We are thrilled to announce our partnership with TD SYNNEX," says Adrian Knapp, CEO and Founder of Aparavi. "This partnership will deliver data management solutions that will help companies understand their unstructured data. When companies are able to identify what data they have, they can mitigate their risk of cyberattack and cut down on increased costs related to the continuous growth of unstructured data." The benefits of this partnership include: Provide customers with a data intelligence and automation platform that delivers end-to-end value; Introduce a simple way to identify the contents within an end-users unstructured data footprint; Deliver the freedom customers need for secure data mobility within a data ecosystem

08:06 EDT TransAct Technologies signs first BOHA! enterprise license sale - TransAct Technologies announced that it has signed its first ever BOHA! software enterprise license Purchase Agreement, covering all 300 locations for a foodservice operator within retail establishments. This agreement for the BOHA! cloud software solution is for a five-year period and features an average revenue per unit ARPU of approximately $950 per year. In addition to the enterprise software license agreement, this customer will purchase 300 BOHA! WorkStation devices to support their labeling needs. The initial installation of 50 locations will occur over the next three months with the remaining locations completed in less than a year. This represents TransAct's largest BOHA! WorkStation order ever, more than doubling the previous record which came in May. "

08:04 EDT Grove Collaborative expands retail footprint - Grove Collaborative (GROV) announced a significant retail expansion for Grove Co., its home care brand. The company added three retailers - Kohl's (KSS), Giant Eagle and Meijer - as it continues to grow its omnichannel presence. Following the brand's launch into retail at Target (TGT) in 2021, Grove Co. has now more than doubled its product assortment in all Target stores and on Target.com to include a broader selection of scents, room spray concentrates, laundry detergent sheets and reusable dish cloths. In recent months, Grove also expanded its retail presence at select Kohl's, Giant Eagle and Meijer store locations with a curated selection of Grove Co.'s cleaning line.

08:03 EDT Humacyte to host KOL webinar on Human Acellular Vessels - Humacyte announced that it will host a key opinion leader webinar on its proprietary Human Acellular Vessels in the treatment of vascular trauma on Thursday, July 14, 2022 at 11:30 a.m. Eastern Time. The webinar will feature presentations from KOLs Ernest Moore, MD and Gregory Magee, MD, who will discuss the current treatment landscape and unmet medical need in the vascular trauma field as well as case studies of trauma patients treated with the HAV. Humacyte's HAV are investigational engineered off-the-shelf replacement vessels initially being developed for vascular repair, reconstruction and replacement. HAV is designed to eliminate the need for harvesting a vessel from a patient or using a synthetic graft, and clinical evidence to date suggests that it is non-immunogenic and infection-resistant and can become durable living tissue.

07:58 EDT Oramed issues letter to shareholders from CEO - Oramed Pharmaceuticals issued a Letter to Shareholders from its Chief Executive Officer, Nadav Kidron. "As we enter the second half of 2022, I am pleased to share with you updates regarding Oramed Pharmaceuticals and our subsidiary Oravax Medical... Our financial position is strong with a robust balance sheet, no debt and approximately $169 million in cash and investments as of March 31, 2022. This position gives us sufficient runway to complete our pivotal oral insulin Phase 3 trials and advance us towards potential FDA approval... In January 2023, we anticipate reaching one of the most significant milestones of this Company's history, when we report top-line efficacy data in the world's first-ever pivotal Phase 3 oral insulin trial for the treatment of type 2 diabetes, under a U.S. FDA protocol... In March 2022, we completed enrollment in our Phase 2 trial of ORMD-0801 for the treatment of non-alcoholic steatohepatitis. We expect to announce top-line results later this quarter... The Phase 1 clinical trial of Oravax's oral virus-like particle COVID-19 vaccine for COVID-naive participants is underway in South Africa. The trial protocol calls for two cohorts each comprised of 12 participants... Due to several factors, including the fact that many volunteers did not qualify during screening due to prior asymptomatic COVID-19 infection and other conditions, the rate of enrollment was slower than anticipated... We expect Cohort B to complete dosing this quarter as well, with data expected in Q4 2022."

07:54 EDT Jacobs awarded $3.9B Engineering, Science contract at NASA - Jacobs was awarded the JSC Engineering, Technology, and Science, JETS, II contract at NASA Johnson Space Center in Houston, Texas. Jacobs is scheduled to begin contract transition on Aug. 1 to continue providing engineering and scientific products and technical services for NASA at Johnson Space Center, JSC. The contract maximum value is estimated at approximately $3.9 billion over 10 years including a five-year base period, two two-year option periods and one one-year option period. "Throughout our 50-year partnership with NASA, Jacobs has shared the agency's commitment to advancing space science and exploration," said Jacobs Chair and CEO Steve Demetriou. "The JETS II contract builds on more than 17 years of continuous support at JSC - a key component of our NASA portfolio, which includes nine locations across the agency. With this latest award from our JSC customer, Jacobs remains well positioned to support the future of human space exploration." Under this contract, Jacobs will provide engineering design, development, sustaining engineering, analysis, assessment, technology development, test services and laboratory/facility operation and maintenance for the JSC Engineering Directorate. Jacobs will also deliver planetary missions research, physical science research, astromaterial curation and laboratory/facility operation and maintenance for the JSC Exploration Integration and Science Directorate, as well as engineering and related services for other organizations at JSC and other Centers and Government Agencies.

07:45 EDT Meridian Bioscience trading resumes

07:41 EDT Biohaven enrolls first patient in Phase 3 trial of taldefgrobep alfa - Biohaven Pharmaceutical announced that it has commenced enrollment in a Phase 3 clinical trial assessing the efficacy and safety of taldefgrobep alfa in Spinal Muscle Atrophy, SMA. Taldefgrobep is an investigational, muscle-targeted recombinant protein with the potential to enhance muscle mass and strength in people living SMA when used in combination with other approved treatments. Irfan Qureshi, M.D., Senior Vice President, Neurology at Biohaven, stated, "This is an important milestone for the taldefgrobep program and for people living with SMA. There have been great strides in advancing therapeutics in this challenging disease. Yet, there remains a significant unmet need to address the residual weakness and functional impairments, such as difficulty walking, that are caused by the disease. We are thankful for the SMA community that has welcomed and worked with us to develop this patient-focused study." RESILIENT, is a Phase 3 placebo-controlled, double-blind trial designed to evaluate the efficacy and safety of taldefgrobep as an adjunctive therapy for participants who are already taking a stable dose of nusinersen or risdiplam or have a history of treatment with onasemnogene abeparvovec-xioi, compared to placebo.

07:38 EDT Enact Holdings enters $200M revolving credit facility - Enact Holdings announced that it entered into a five-year $200 million senior unsecured revolving credit facility on June 30, 2022. The company may use borrowings under the Credit Facility for working capital needs and general corporate purposes, including capital contributions to our insurance subsidiaries. Borrowings under the Credit Facility will accrue interest at a floating rate tied to a standard short-term borrowing index plus an applicable margin, which is based on the company's ratings and currently stands at 200 basis points. As of the closing date, no amounts have been borrowed under the Credit Facility. Additional details related to the terms and conditions of the Credit Facility are included in the credit agreement. The Credit Facility was entered into with five banks, led by JPMorgan Chase Bank, N.A. as Administrative Agent and Joint Lead Arranger and Truist Bank as Joint Lead Arranger, along with Goldman Sachs Bank USA, Barclays Bank PLC and Citibank, N.A.

07:35 EDT Intercept says OCA 25 meets primary endpoint in Phase 3 REGENERATE study - Intercept Pharmaceuticals announced topline results from a new interim analysis of its ongoing pivotal Phase 3 REGENERATE trial of OCA in patients with liver fibrosis due to nonalcoholic steatohepatitis. This is the second analysis in which OCA has met the primary endpoint for the intent-to-treat population in REGENERATE and based on these results, Intercept will be re-submitting its NDA for OCA in liver fibrosis due to NASH. In this new interim analysis of the ITT population from REGENERATE, 22.4% of subjects randomized to once-daily oral OCA 25 mg met the primary endpoint of achieving at least one stage of fibrosis improvement with no worsening of NASH at month 18 on liver biopsy compared with 9.6% of subjects on placebo. These results are consistent with the original positive analysis announced in February 2019, which also showed that OCA 25 mg had a statistically significant effect on fibrosis improvement. The population in this new interim analysis mirrored the original analysis population from 2019 but used a consensus panel approach to histology reads, in line with recent U.S. Food and Drug Administration guidance, while the original analysis relied on results from individual central readers. A numerically greater proportion of individuals in the OCA 25 mg treatment group compared to placebo achieved the endpoint of resolution of NASH with no worsening of liver fibrosis but, consistent with the original analysis, this did not reach statistical significance. For the primary objective to be met, the study was required to achieve only one of the two primary endpoints. Safety was evaluated in 2,477 subjects who took at least one dose of study drug. Compared to the original analysis, the safety population in this new interim analysis had significantly longer exposure to study drug, yielding more than 8,000 total patient-years and 3.4 times more exposure. Nearly 1,000 subjects had been on study drug for four years. Treatment-emergent adverse events, treatment-emergent serious adverse events, and deaths were generally balanced across the OCA and placebo treatment groups. The most common TEAE was pruritus and pruritus was the most common cause for treatment discontinuation. Serious gallbladder-related events occurred in less than3% of subjects in any treatment group and, consistent with its known mechanism of action, OCA 25 mg had higher rates of biliary events including gallstones. Independent groups of experts reviewed certain categories of safety events to provide a blinded adjudication as specifically requested by FDA. These included events pertaining to hepatic safety, cardiovascular and renal. Topline analysis through four years of treatment showed a numerically higher number of adjudicated hepatic safety events for OCA 25 mg, the vast majority of which were mild in severity. For adjudicated core major adverse cardiovascular events and adjudicated acute kidney injury events, frequency of events was low and balanced across treatment groups. Consistent with its mechanism of action as an FXR agonist, OCA treatment was associated with an increase in LDL at Month 1 which returned to near baseline values by Month 12. Changes in other blood chemistries including ALP, GGT, AST, and ALT also showed evidence of FXR mediated activity, supporting the dose-response of OCA. In REGENERATE, patients with biopsy-proven stage 2 or 3 liver fibrosis due to NASH were randomized 1:1:1 to receive placebo, OCA 10 mg, or OCA 25 mg once daily. A second biopsy was conducted in these 931 subjects at Month 18 for the planned interim analysis. The new interim analysis was based on a reassessment of the baseline and Month 18 liver biopsies using a consensus reading methodology. Consensus panels were comprised of three board-certified pathologists who demonstrated accuracy and reproducibility in their assessments of liver biopsies during proficiency testing. The consensus panels in this new interim analysis reviewed digitized whole slide images of the same glass slides of liver biopsy tissue that were evaluated in the original analysis using individual central readers.

07:32 EDT Sellas Life Sciences adds dose cohort in Phase 1 trial of CDK9 inhibitor - Sellas Life Sciences has added a second, once-a-week dose cohort in its ongoing global Phase 1 clinical trial in both the U.S. and China with the highly selective CDK9 inhibitor GFH009 for patients suffering from advanced relapsed or refractory lymphoma and acute myeloid leukemia - AML -. Sellas previously reported that AML patients treated twice-a-week at the 22.5mg dose level experienced no dose-limiting toxicities. The patients in the AML arm of the clinical trial have entered the last twice-a-week 30mg planned dose level. Additionally, enrollment for lymphoma patients at the twice-a-week 15mg dose level cohort has been completed and safety assessments are underway. The twice-a-week dose regimens for both groups will proceed as planned and are on target for completion this year.

07:31 EDT Meridian Bioscience trading halted, news pending

07:25 EDT Meridian to be acquired by SD Biosensor, SJL Partners for $34 per share in cash - Meridian Bioscience and SD Biosensor and SJL Partners announced that they have entered into a definitive merger agreement whereby a newly formed affiliate vehicle of the Consortium will acquire Meridian in an all-cash transaction valued at approximately $1.53B. Under the terms of the agreement, Meridian shareholders will receive $34.00 per share in cash, which represents a premium of approximately 32% over Meridian's closing stock price on the day before the Consortium's first offer before the market open on March 18, 2022 and a premium of 16% based on the one-month average price per share of common stock commencing June 7, 2022. "We are excited to announce this new chapter for Meridian after the many years spent transforming the Company for sustainable growth," commented Jack Kenny, Meridian's Chief Executive Officer. "In addition to delivering immediate and significant value to our shareholders, we believe the transaction will enhance our ability to serve customers as we navigate the decline in COVID-19 testing demand and develop new products with the benefit of SDB's industry expertise and complementary offerings. Current and prospective employees around the world will also benefit from an even stronger Meridian supported by SDB's and SJL's financial backing and experience. I look forward to working with SDB and SJL and the rest of our Meridian team to build long-term strength and drive further growth in the diagnostics space." Under the terms of the merger agreement, which has been unanimously approved by the boards of directors of Meridian and SDB, and the investment committee of SJL, the newly formed vehicle will acquire 100% of the outstanding shares of the Company. The transaction is subject to approval by Meridian shareholders, receipt of required regulatory approvals, the absence of specified materially adverse outcomes of Meridian's previously disclosed and ongoing investigation by the U.S. Department of Justice, and other customary closing conditions. The transaction is expected to close in the fourth calendar quarter of 2022. Upon completion of the transaction, it is expected that SDB will own approximately 60% and SJL will own approximately 40% of Meridian. Meridian will no longer be traded or listed on any public securities exchange.

07:18 EDT Freehold to acquire U.S. Midland basin, Eagle Ford basin assets for C$155M - Freehold Royalties has entered into definitive agreements with two private sellers to acquire high-quality U.S. mineral title and royalty assets located in the Midland basin predominantly in Howard County, Texas for C$123 million and in the Eagle Ford basin in Texas for C$32 million, both figures net of estimates for exchange rates and customary closing adjustments. Freehold also recently closed its previously announced C$19 million acquisition of mineral title and royalty assets in the Midland basin. The U.S. Acquisitions enhance the quality of Freehold's North American royalty portfolio through further strengthening of our peer leading realized commodity pricing, building on the production growth platform we have established in the Permian basin, and continuing to position our portfolio in the highest quality oil and gas development areas across North America. The execution of our business strategy is focused on continuously improving both the near-term and long-term sustainability of Freehold's dividend, maintaining balance sheet strength and flexibility, and retaining the ability to return capital to our shareholders through multiple years of free cash flow generation. The U.S. Acquisitions are expected to add approximately 1,100 boe/d in production volumes and C$31 million in funds from operations in 2023 while growing our U.S. land holdings by approximately 147,000 gross acres and 8,000 net royalty acres. The U.S. Acquisitions will be funded through the utilization of Freehold's existing credit facility. Freehold will provide an update on its 2022 guidance and payout levels as part of its Q2-2022 release after market close on August 9, 2022.

07:14 EDT Absci enters multi-program collaboration with biotech partner - Absci has entered into a collaboration agreement with an undisclosed biotech partner. The partner is a stealth-mode company, led by pedigreed biotech industry executives, focused on discovery and development of antibody-drug-conjugates initially for oncology indications. The partner company has developed novel, proprietary warhead linker chemistries that it will target to specified sites on subject antibodies by exploiting Absci's Bionic Protein non-standard amino acid incorporation technology. Financial terms are not being disclosed, but they include an upfront payment as well as future milestones and royalties associated with each program.

07:12 EDT Gilat Satellite awarded follow-on network expansion orders from Asian nation - Gilat Satellite was awarded follow-on orders for the expansion of a defense force satellite communication - SATCOM - network in an Asian nation. Gilat's SkyEdge II-c hubs and Capricorn VSATs are being deployed to serve the specialized needs of the customer.

07:11 EDT Asante Gold announces first pour at Bibiani Gold Mine - Asante Gold Corporation is pleased to announce that the first gold pour at the Bibiani Gold Mine has been completed with process of gravity gold concentrate recovered by the Knelson Concentrator. Asante acquired the Bibiani Gold Mine in August 2021 and completed its project execution plan that included refurbishment and upgrade of the Process Plant, Tailings Storage Facility and Mine Site Infrastructure. In September 2021, Asante announced start of the refurbishment process and the Company's plan to pour gold in Q3 2022. In early June 2022, Asante announced the start of commissioning and operation of the Bibiani Process Plant. Since July 1, 2022, 24 hour per day operation has proceeded with the Carbon-in-Leach, carbon stripping and elution areas now operating. Hot Commissioning of the Gold Refinery was completed on July 7th. This is the final operating area of the Process Plant to be commissioned. Scale up of production is continuing as planned, including collection of gold on carbon, leading to delivery of approximately 175,000 oz gold over the next 12 months.

07:10 EDT Solaris provides update on activities at Warintza project, spin-out - Solaris Resources provides an update on activities at its Warintza Project in southeastern Ecuador, including an update on its regional exploration program which has identified a number of new targets for further exploration in support of drilling, and progress on the proposed spin-out to create Solaris Exploration Inc. Exploration activities at the Warintza Project continue with seven drill rigs targeting high value growth of the recently reported Warintza Mineral Resource Estimate, with drilling at Warintza Central targeting extensions to near surface, high-grade mineralization, and major growth targeted from the expansion of drill coverage at Warintza East within a largely undrilled footprint. With the protests in Ecuador having concluded on June 30, the flow of samples from the Company's core processing facility to its prep lab, which has now resumed operations, and onward for final assay in Lima has restarted, with a considerable backlog of assays pending. Regional Exploration Update: Solaris has undertaken the first significant program of regional exploration at Warintza since the original stream sediment sampling program that identified the Warintza porphyry cluster in the 1990s. This work has identified additional porphyry targets, potentially expanding the footprint of the cluster to the northeast, and possibly a new area of porphyry emplacement to the west, approximately halfway to the adjacent San Carlos copper porphyry deposit. In addition, this work has established a series of skarn targets, as well as a large high sulphidation epithermal target adjacent to the Warintza porphyry cluster where overlapping mineralized porphyries have intruded a layered sequence of carbonate and volcanic rocks that have provided a fertile setting to develop these styles of mineralization. Solaris continues to advance the proposed spin-out and has made considerable progress with the internal re-organization of the Company, its subsidiaries and mineral concessions including the transfer of its non-core assets held in Ecuador outside of the Warintza porphyry cluster, Peru, Chile and Mexico into a newly incorporated wholly-owned subsidiary of Solaris named Solaris Exploration Inc. Following the internal re-organization, it is expected that 100% of the common shares of Solaris Exploration Inc. will be spun out to shareholders of Solaris relative to their shareholdings.

07:06 EDT TScan Therapeutics appoints Debora Barton as Chief Medical Officer - TScan Therapeutics appointed Debora Barton as Chief Medical Officer. Prior to joining TScan, Barton was the Chief Medical Officer at Carisma Therapeutics, where she was responsible for clinical development, clinical operations, medical affairs, and safety. Previously Barton was the Senior Vice President, Head of Clinical, Head of Safety at Iovance Biotherapeutics, where she oversaw several Phase 2 studies in solid tumors and led clinical efforts related to regulatory interactions.

07:04 EDT MediWound's EscharEx shows positive Phase 2 results in leg ulcers - MediWound announced positive results from its U.S. prospective, open-label, single-arm, Phase 2 pharmacology clinical study of EscharEx for the debridement of lower leg ulcers. The study was designed to evaluate the clinical performance, safety and pharmacology effect of EscharEx in debridement of venous leg ulcers - VLUs - and diabetic foot ulcers - DFUs -. 70% of patients achieved complete debridement during the course of treatment within up to 8 applications. On average, complete debridement was achieved after 3.9 applications of EscharEx. Additionally, an average reduction of 35% in wound size was achieved by the end of the 2-week follow-up period. Biomarker analysis from wound fluid is on-going and safety data shows that EscharEx is safe and well-tolerated. The study evaluated the clinical performance, safety, and pharmacology effect of EscharEx in the debridement of lower leg ulcers. The study evaluated the safety and efficacy of debridement as measured by incidence of, and time to complete debridement.

07:04 EDT Azure becomes first renewable energy company in India to be SA8000 certified - Azure Power announced that it has been awarded SA8000:2014 certification, an international standard for social accountability. Azure Power is the first Renewable Energy company in India to have been awarded this certification. Harsh Shah, CEO, Azure Power said, "Social responsibility is core to how we conduct our business, including our supply chain. Benchmarking against high global standards help us to maintain, strengthen and demonstrate our commitment to adhere to highest social standards of corporate governance. It further provides assurance to our stakeholders on the company's social performance and commitment to conduct business in a socially responsible manner."

07:02 EDT Driven Brands acquires fifth US auto glass brand, K&K Glass - Driven Brands announces the continued expansion of its auto glass offering in the U.S. with the acquisition of leading Florida-based K&K Glass. Driven Brands' fifth U.S. automotive glass acquisition will be reported in its Paint, Collision, and Glass segment. "We were proud to kickstart our entry into the U.S. automotive glass market with the acquisition of Auto Glass Now," said Michael Macaluso, EVP and paint, collision, and glass group president, Driven Brands. "Since then, we've added All Star Glass, A1 Auto Glass and Perfection Auto Glass, in addition to building new locations in North Carolina and Texas. We remain highly acquisitive in this segment as we look to support the needs of our customers in this extremely fragmented industry. It's an exciting time to join our Driven Brands family and we are thrilled to now welcome K&K Glass."

06:59 EDT Asensus announces installation of Senhance Surgical System at German hospital - Asensus Surgical announced the installation of a Senhance Surgical System in the Department of Gynecology at the University Hospital Tubingen. The Department of Gynecology at the University Hospital Tubingen previously initiated its Senhance Surgical program in December of 2021, as announced by the Company on January 10, 2022. The system will be initially utilized by the Department of Gynecology at the University Hospital Tubingen. Independent of the lease and utilization agreement, the Department of Gynecology at the University Hospital Tubingen has entered into a research agreement with the Company focused on collecting procedural and outcomes data for certain gynecologic procedures performed with the Senhance system.

06:58 EDT NovaBay's DERMAdoctor products to be featured at CosmoProf North America - NovaBay announces that its DERMAdoctor product collections will be featured at Cosmoprof North America. "We're thrilled about connecting in-person with retailers and other professionals at the most important beauty industry networking opportunity held annually in the U.S.," said Audrey Kunin, MD, NovaBay's Chief Product Officer and a board-certified dermatologist. "The DERMAdoctor team will be showcasing products that offer innovative treatments that address commonly overlooked skin concerns and target specific underserved segments of the skincare market. Each formulation is designed to be elegant, hypoallergenic and highly effective while addressing multiple customer needs, all without the need for a prescription. We invite retailers to explore our DERMAdoctor collections and meet with us at booth 34050 on the exhibition floor."

06:55 EDT RVL Pharmaceuticals announces preliminary Q2 UPNEEQ sales of $8.4M - RVL Pharmaceuticals announced preliminary second quarter 2022 net product sales of UPNEEQ of $8.4 million. The Company also announced that from February through June of 2022 it had received orders from approximately 2,200 cumulative unique medical aesthetics practices. The Company also reaffirms its guidance targeting net product sales of UPNEEQ for the fourth quarter of 2022 of $20 to $25 million. "We are delighted with our year-to-date sales momentum, as we continue to demonstrate UPNEEQ's potential within the eyecare and medical aesthetics markets. During the second quarter of 2022, we continued to expand the number of medical aesthetics practices that have purchased UPNEEQ- doubling the number of providers since the end of the first quarter. In addition, we also worked diligently to begin to establish UPNEEQ as an integrated part of the medical aesthetics practice, which resulted in over 500 practices having re-purchased UPNEEQ by the end of the second quarter - an indication of the opportunity in this market. The enthusiasm from patients and providers has been encouraging and we are on our way to establishing a strong foundation for the adoption of UPNEEQ as an integral piece of the minimally/non-invasive facial aesthetics category," stated Brian Markison, Chief Executive Officer of RVL. "As planned and previously announced, we expect to significantly expand our medical aesthetics salesforce by mid to late July and believe that we are well positioned to build on our momentum and achieve our fourth quarter 2022 net sales projection."

06:39 EDT Charah Solutions awarded multi-year fly ash sales, marketing contract - Charah Solutions announced that it has been awarded a multi-year contract from an Indiana regulated utility for the marketing and sustainable recycling of fly ash. The multi-year project will begin in Q3 2022. Under the terms of the contract, Charah Solutions will be responsible for the utilization of approximately 150,000 tons per year of specification grade fly ash. The fly ash will be distributed through Charah Solutions' MultiSource materials network, a unique distribution system of nearly 40 nationwide locations, with international sourcing and distribution. The MultiSource network provides a continuous and reliable supply of supplementary cementitious materials to cement and concrete producers to make concrete, as well as to other customers who beneficially reuse the products. It is anticipated that 100% of the fly ash will be shipped by truck to markets in the Midwest.

06:36 EDT Thor Industries' Vice President of Investor Relations Mark Trinske to retire - Thor Industries announced that Mark Trinske, Vice President of Investor Relations, will be retiring at the end of the company's fiscal year on July 31. As part of the planned transition, Michael Cieslak, CFA, Thor 's Investor Relations Manager will be responsible for Thor's investor relations efforts going forward. Cieslak joined the company in February 2020 with a background in investor relations and financial planning and analysis.

06:34 EDT Henry Schein completes acquisition of Condor Dental - Henry Schein has completed the acquisition of Condor Dental, a dental distribution company that serves dental general practitioners, specialists, and laboratories in Switzerland. This transaction is expected to be neutral to Henry Schein's 2022 diluted earnings per share and to be accretive thereafter. Financial terms were not disclosed. Condor Dental is based in Vouvry, Switzerland, and was established in 1978. Sales for 2021 were approximately $18M, the majority of which were from dental consumable merchandise, with further revenue from the design and customization of dental practices and dental laboratory installations.

06:32 EDT BitNile' subsidiary Ault Alliance did not acquire EYP - BitNile's subsidiary Ault Alliance did not acquire the assets of EYP and its affiliates. The asset purchase agreement constituted a "stalking horse" bid in a sale process being conducted under Section 363 of the U.S. Bankruptcy Code. The prevailing bidder under the sale process was Page Southerland Page. Ault Alliance lent $8.0M to EYP and earned $4.7M in interest, penalties and break-up fees from October 2021 through June 2022. The principal amount of the loans, interest, penalties and break-up fees, were fully repaid on June 30, 2022, though the company did incur certain expenses that it will be responsible for that will not be covered by any of the foregoing payments to the company.

06:17 EDT FDA discusses efforts to increase infant formula supply - On Feb. 17, 2022, the FDA warned consumers not to use certain powdered infant formula products from Abbott Nutrition's Sturgis, Michigan infant formula production facility. Abbott voluntarily ceased production at the facility as well as initiated a voluntary recall of certain products. "We know the recall and facility shutdown have created hardships obtaining infant formula, particularly given the overall strains on supply chains experienced during the COVID-19 pandemic," the FDA said. More infant formula will be available in the weeks and months ahead. How the FDA is working to increase supply: 1) Working with current infant formula producers that service the U.S. market to increase production. This includes working with the U.S. Department of Health and Human Services to use the Defense Production Act to ensure ingredients are available to sustain this production. 2) Exercising flexibility by allowing the import of certain infant formula products from abroad that will result in millions of cans of infant formula being available on U.S. store shelves beginning in June 2022. 3) Working closely with U.S. partners and domestic and international manufacturers to immediately increase the availability of specialized medical infant formula available in the U.S. 4) Working with Abbott Nutrition (ABT) under a consent decree to ensure Abbott Nutrition's Sturgis, Michigan facility resumes production in a safe and sanitary manner. 5) Sharing tips with consumers on how to safely prepare imported infant formula. Reckitt Benckiser (RBGLY) is another publicly traded company in the space.

06:11 EDT Franklin Templeton agrees to lease at Armada Hoffler's Wills Wharf - Armada Hoffler announced that it has executed a new office lease with Franklin Templeton for 60,000 square feet at the Company's Wills Wharf office building in Baltimore's Harbor Point neighborhood. The investment management firm has agreed to lease the entire fifth floor and a portion of the fourth floor of Wills Wharf and will bring the building to 91% occupancy. Franklin Templeton will join a dynamic roster of corporate office tenants at Harbor Point, including T. Rowe Price, Exelon Constellation, Transamerica, Morgan Stanley, EY, and RBC Wealth.

06:08 EDT Deluxe appoints Jean Herrick as CHRO, Cameron Potts as CCO - Deluxe recently announced the promotion of two leaders to the executive level. Jean Herrick, previously Vice President of Human Resources, has been promoted to Senior Vice President and Chief Human Resources Officer. Cameron Potts, previously Vice President of Corporate Communications, has been promoted to Senior Vice President and Chief Communications Officer.

06:05 EDT Immuron granted European patent for treatment of Clostridioides difficile - Immuron has received notification of the Intent to Grant a European Patent for compositions and methods for the treatment and/or prophylaxis of Clostridioides difficile associated disease. The European registration once formally granted will add to Immuron's patent position for compositions and methods for the treatment and/or prophylaxis of Clostridioides difficile associated disease in Australia, New Zealand and the U.S. Clostridioides difficile infection, or CDI, is a disease of the large intestine caused by toxins produced by the spore forming bacterium Clostridioides difficile. CDI can also result in serious disease complications including bowel perforation, toxic megacolon and sepsis, and it can prove fatal in the most severe cases. It is estimated that CDI affects up to 1.2% of hospitalized patients in the United States, representing an estimated cost of $4.8B per year.

05:56 EDT Shell revises up value of oil and gas assets ahead of July 28 results - Shell said in a trading update ahead of its July 28 results that it would reverse up to $4.5B in writedowns on oil and gas assets after it raised its energy prices outlook following Russia's invasion of Ukraine. "In the second quarter 2022, Shell has revised its mid and long-term Oil and Gas commodity prices reflecting the current macroeconomic environment as well as updated energy market demand and supply fundamentals. This resulted in a review of Shell's Upstream and Integrated Gas previously impaired assets." In the update before second quarter results, Shell said its refining margins almost tripled over the period, boosted by recovering global demand from the pandemic, a lack of refining capacity and lower fuel exports from Russia. Earnings from oil and refined products trading were expected to be strong in the quarter but lower than the first quarter of 2022, Shell said. Shell's indicative refining margin rose in the second quarter to $28.04 per barrel from $10.23 a barrel in the first quarter and $4.17 a year earlier. The upgrade will result in post-tax impairment reversals of $3.5B-$4.5B. Shell also announced that the share buyback program of $8.5B announced for the first half of 2022 was completed on July 5.

05:10 EDT Exelixis, Ryvu enter exclusive license agreement for STING technology - Exelixis and Ryvu Therapeutics announced that the companies have entered into an exclusive license agreement focused on the development of novel targeted therapies utilizing Ryvu's STING technology. The agreement expands Exelixis' portfolio of biotherapeutics by combining Ryvu's proprietary small molecule STING agonists and STING biology know-how with Exelixis' network in antibody engineering, antibody-drug conjugate, or ADC, technologies, and history of developing and commercializing oncology therapeutics. Under the terms of the agreement, Exelixis will pay Ryvu an upfront fee of $3M in exchange for certain rights to Ryvu's STING agonist small molecules, which Exelixis will seek to incorporate into targeted therapies such as ADCs. Exelixis will lead all research activities and, upon selection of each development candidate, will be responsible for all development and commercialization activities. Ryvu will provide guidance and know-how during the early research phase of the partnership, and will be eligible to receive development, regulatory and commercialization milestone payments, as well as tiered royalties on the annual net sales of any products that are successfully commercialized under the collaboration. Ryvu will also retain all development and commercial rights to develop its STING agonist portfolio as standalone small molecules.

05:03 EDT Amazon announces Prime Day deals - Prime Day kicks off July 12 at 3 a.m. EDT, offering deals of up to 79% off across categories, including electronics, devices, toys, beauty, fashion, and home, from brands and small businesses. This Prime Day, Amazon will offer savings for members including Amazon's lowest prices ever on select Bose and Sony headphones. Prime Day will also offer customers the lowest price ever for Fire TV smart TVs on Amazon, including deals for a $49.99 Insignia 32-inch Smart HD Fire TV and a $99.99 Amazon Fire TV 50-inch 4K UHD Smart TV. The company said, "Prime offers the best of shopping, savings, and entertainment to more than 200 million paid members around the world. In the U.S., that includes unlimited access to award-winning movies and series with Prime Video, ad-free listening of 2 million songs, thousands of stations and playlists, and thousands of podcasts with Amazon Music, free games with Prime Gaming, more than 3,000 books and magazines with Prime Reading, unlimited photo storage with Amazon Photos, and incredible savings with Prime Day. Prime was built on the foundation of unlimited fast, free shipping. Prime members enjoy ultrafast grocery delivery and pickup from Amazon Fresh and Whole Foods Market in more than 5,000 cities and towns, free Same-Day Delivery on hundreds of thousands of items in over 90 major metropolitan areas, and free One-Day Delivery on more than 20 million items coast to coast. Prime members also receive fast, free delivery on prescriptions from Amazon Pharmacy and prescription savings at more than 60,000 participating pharmacies in the U.S."